SG11201909552VA - Combination therapy for prostate cancer - Google Patents
Combination therapy for prostate cancerInfo
- Publication number
- SG11201909552VA SG11201909552VA SG11201909552VA SG11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- johnson
- effective amount
- therapeutically effective
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT omit VIII °nolo VIII 010 mumom oimIE (10) International Publication Number WO 2018/191141 Al (51) International Patent Classification: A61K 31/454 (2006.01) A61K 31/58 (2006.01) A61K 31/573 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/026661 (22) International Filing Date: Published: — with international search report (Art. 21(3)) 09 April 2018 (09.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/485,164 13 April 2017 (13.04.2017) US (71) Applicant: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventor; and (71) Applicant US only): YU, Margaret K. [US/US]; 10990 Wilshire Blvd, Suite 300, Los Angeles, California 90024 (US). (72) Inventors: YU, Margaret K.; 10990 Wilshire Blvd., Suite 300, Los Angeles, California 90024 (US). SNYDER, Lin- da Anne; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). = (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 71' 1-1 KM, ML, MR, NE, SN, TD, TG). 1-1 1-1 1-1 (54) Title: COMBINATION THERAPY FOR PROSTATE CANCER (57) : Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a 0 therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., \" abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485164P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/026661 WO2018191141A1 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909552VA true SG11201909552VA (en) | 2019-11-28 |
Family
ID=62067858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909552V SG11201909552VA (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20180296574A1 (en) |
| EP (3) | EP4176878A1 (en) |
| JP (3) | JP7141408B2 (en) |
| KR (1) | KR20190134718A (en) |
| CN (1) | CN110753545A (en) |
| AU (2) | AU2018251594A1 (en) |
| BR (1) | BR112019021466A2 (en) |
| CA (1) | CA3059562A1 (en) |
| CL (1) | CL2019002871A1 (en) |
| CO (1) | CO2019011591A2 (en) |
| CR (1) | CR20190467A (en) |
| DK (1) | DK3609497T3 (en) |
| DO (1) | DOP2019000264A (en) |
| EA (1) | EA201992430A1 (en) |
| ES (1) | ES2931052T3 (en) |
| HR (1) | HRP20221327T1 (en) |
| HU (1) | HUE060460T2 (en) |
| JO (1) | JOP20190244A1 (en) |
| LT (1) | LT3609497T (en) |
| MA (1) | MA48728B1 (en) |
| MD (1) | MD3609497T2 (en) |
| MX (1) | MX2019012296A (en) |
| NI (1) | NI201900105A (en) |
| PE (1) | PE20200444A1 (en) |
| PH (1) | PH12019502317A1 (en) |
| PL (1) | PL3609497T3 (en) |
| PT (1) | PT3609497T (en) |
| RS (1) | RS63832B1 (en) |
| SG (1) | SG11201909552VA (en) |
| WO (1) | WO2018191141A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019522032A (en) | 2016-07-29 | 2019-08-08 | ヤンセン ファーマシューティカ エヌ．ベー． | How to treat prostate cancer |
| WO2020139339A1 (en) * | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| CN113546037A (en) * | 2020-04-20 | 2021-10-26 | 鲁南制药集团股份有限公司 | Abiraterone acetate suppository and preparation method thereof |
| CA3177094A1 (en) * | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib |
| US11806313B2 (en) | 2021-12-15 | 2023-11-07 | Hunan Huize Biopharma S&T Co., Ltd. | Abiraterone acetate containing composition and application thereof |
| CN114306236B (en) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | Self-microemulsion system for loading abiraterone acetate, composition and application |
| WO2023194525A1 (en) * | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Combination therapy for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306977A (en) * | 2006-08-25 | 2015-01-28 | 库伽尔生物科技公司 | Methods and compositions for treating cancer |
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| EP2109608B1 (en) * | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| CN106008460B (en) | 2008-01-08 | 2022-08-12 | 默沙东公司 | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| WO2014089324A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
-
2017
- 2017-06-16 JO JOP/2019/0244A patent/JOP20190244A1/en unknown
-
2018
- 2018-04-09 HR HRP20221327TT patent/HRP20221327T1/en unknown
- 2018-04-09 JP JP2019555852A patent/JP7141408B2/en active Active
- 2018-04-09 SG SG11201909552V patent/SG11201909552VA/en unknown
- 2018-04-09 CN CN201880039365.1A patent/CN110753545A/en active Pending
- 2018-04-09 RS RS20221127A patent/RS63832B1/en unknown
- 2018-04-09 PL PL18720895.4T patent/PL3609497T3/en unknown
- 2018-04-09 PE PE2019002030A patent/PE20200444A1/en unknown
- 2018-04-09 EP EP22200801.3A patent/EP4176878A1/en active Pending
- 2018-04-09 KR KR1020197032257A patent/KR20190134718A/en not_active Application Discontinuation
- 2018-04-09 PT PT187208954T patent/PT3609497T/en unknown
- 2018-04-09 MX MX2019012296A patent/MX2019012296A/en unknown
- 2018-04-09 EP EP18720895.4A patent/EP3609497B1/en active Active
- 2018-04-09 WO PCT/US2018/026661 patent/WO2018191141A1/en active Application Filing
- 2018-04-09 EP EP22200882.3A patent/EP4176879A1/en not_active Withdrawn
- 2018-04-09 AU AU2018251594A patent/AU2018251594A1/en not_active Abandoned
- 2018-04-09 EA EA201992430A patent/EA201992430A1/en unknown
- 2018-04-09 CA CA3059562A patent/CA3059562A1/en active Pending
- 2018-04-09 ES ES18720895T patent/ES2931052T3/en active Active
- 2018-04-09 LT LTEPPCT/US2018/026661T patent/LT3609497T/en unknown
- 2018-04-09 HU HUE18720895A patent/HUE060460T2/en unknown
- 2018-04-09 BR BR112019021466-6A patent/BR112019021466A2/en active Search and Examination
- 2018-04-09 CR CR20190467A patent/CR20190467A/en unknown
- 2018-04-09 MA MA48728A patent/MA48728B1/en unknown
- 2018-04-09 DK DK18720895.4T patent/DK3609497T3/en active
- 2018-04-09 MD MDE20200190T patent/MD3609497T2/en unknown
- 2018-04-11 US US15/950,707 patent/US20180296574A1/en active Pending
-
2019
- 2019-10-08 CL CL2019002871A patent/CL2019002871A1/en unknown
- 2019-10-09 NI NI201900105A patent/NI201900105A/en unknown
- 2019-10-10 PH PH12019502317A patent/PH12019502317A1/en unknown
- 2019-10-14 DO DO2019000264A patent/DOP2019000264A/en unknown
- 2019-10-18 CO CONC2019/0011591A patent/CO2019011591A2/en unknown
-
2022
- 2022-02-25 US US17/680,553 patent/US20220175801A1/en not_active Abandoned
- 2022-07-22 JP JP2022117192A patent/JP7407880B2/en active Active
-
2023
- 2023-11-20 JP JP2023196574A patent/JP2024023344A/en active Pending
-
2024
- 2024-04-11 AU AU2024202346A patent/AU2024202346A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909552VA (en) | Combination therapy for prostate cancer | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201909325RA (en) | 2-amino-quinoline derivatives | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201901715UA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201900361RA (en) | Methods of treating prostate cancer |